Real-World Dosing Patterns in Patients with Anaplastic Lymphoma Kinase Positive ( ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated with Brigatinib in the Front-Line(FL) Setting in the United States: A Claims Database Analysis
07:30am - 03:45pm EDT - April 1, 2023
07:30am - 03:45pm EDT - April 1, 2023
Author(s):
- Edmund W. Tai, MD, Hematologist=oncologsit, Sutter Health
Tags: Outcomes and Health Services Research
| Display Label | Action |
|---|---|
| AC23P87 - Real-World Dosing Patterns in Patients with Anaplastic Lymphoma Kinase Positive ( ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated with Brigatinib in the Front-Line(FL) Setting in the United States: A Claims Database Analysis | Download MP3 |
| 087-General Poster Session | Download Handout |
